Applied DNA Sciences Files 8-K on Financials
Ticker: BNBX · Form: 8-K · Filed: Aug 14, 2025 · CIK: 744452
Sentiment: neutral
Topics: financial-condition, results-of-operations, filing
Related Tickers: APDN
TL;DR
APDN dropped an 8-K on financials, check it out.
AI Summary
Applied DNA Sciences, Inc. filed an 8-K on August 14, 2025, reporting on its results of operations and financial condition, and including financial statements and exhibits. The filing details the company's financial performance and provides supporting documentation.
Why It Matters
This filing provides investors with crucial updates on Applied DNA Sciences' financial health and operational performance, impacting investment decisions.
Risk Assessment
Risk Level: medium — 8-K filings can contain significant financial information that may lead to stock price volatility.
Key Players & Entities
- Applied DNA Sciences, Inc. (company) — Registrant
- 001-36745 (company) — Commission File Number
- 59-2262718 (company) — IRS Employer Identification No.
- August 14, 2025 (date) — Date of earliest event reported
FAQ
What specific financial information is being reported in this 8-K?
The 8-K filing indicates it pertains to 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits'.
When was this 8-K filing submitted?
The filing was submitted on August 14, 2025.
What is the Commission File Number for Applied DNA Sciences, Inc.?
The Commission File Number is 001-36745.
What is the IRS Employer Identification Number for Applied DNA Sciences, Inc.?
The IRS Employer Identification Number is 59-2262718.
What is the primary business address of Applied DNA Sciences, Inc.?
The primary business address is 50 Health Sciences Drive, Stony Brook, NY 11790.
Filing Stats: 573 words · 2 min read · ~2 pages · Grade level 10.2 · Accepted 2025-08-14 16:16:44
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value APDN The Nasdaq Stock Mar
Filing Documents
- tm2523531d1_8k.htm (8-K) — 28KB
- tm2523531d1_ex99-1.htm (EX-99.1) — 153KB
- tm2523531d1_ex99-1img001.jpg (GRAPHIC) — 17KB
- 0001104659-25-078611.txt ( ) — 380KB
- apdn-20250814.xsd (EX-101.SCH) — 3KB
- apdn-20250814_lab.xml (EX-101.LAB) — 33KB
- apdn-20250814_pre.xml (EX-101.PRE) — 22KB
- tm2523531d1_8k_htm.xml (XML) — 3KB
02 Results of Operations and Financial
Item 2.02 Results of Operations and Financial Condition. On August 14, 2025, Applied DNA Sciences, Inc. (the "Company") issued a press release announcing its results of operations for the quarterly period ended June 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information furnished pursuant to this Item 2.02, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities under that Section and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. ( d) Exhibits Exhibit No. Description 99.1 Press Release issued by Applied DNA Sciences, Inc. dated August 14, 2025 regarding results of operations for the quarterly period ended June 30, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: August 14, 2025 APPLIED DNA SCIENCES, INC. By: /s/ Judith Murrah Name: Judith Murrah Title: Chief Executive Officer EXHIBIT INDEX Exhibit No. Description 99.1 Press Release issued by Applied DNA Sciences, Inc. dated August 14, 2025 regarding results of operations for the quarterly period ended June 30, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).